转换抑制
交易激励
糖皮质激素受体
虚拟筛选
化学
生物信息学
对接(动物)
IC50型
受体
药理学
转录因子
药物发现
生物化学
医学
体外
基因
护理部
作者
Xueping Hu,Jinping Pang,Changwei Chen,Dejun Jiang,Chao Shen,Xin Chai,Yang Liu,Xujun Zhang,Lei Xu,Sunliang Cui,Tingjun Hou,Dan Li
标识
DOI:10.1016/j.ejmech.2022.114382
摘要
Glucocorticoids (GCs) are the most commonly used anti-inflammatory drugs. However, their excellent therapeutic effects are often accompanied by undesirable side effects. To discover selective glucocorticoid receptor modulators (SGRMs) that preferentially induce transrepression with little or no transactivation activity, a structure-based virtual screening by combining molecular docking and InteractionGraphNet (IGN) rescoring was performed, and compound HP210 was identified. HP210 did not induce the transactivation functions of GR while still acted on the NF-κB mediated tethered transrepression function (IC50 = 2.32 μM), and suppressed the secretion of pro-inflammation cytokines IL-1β and IL-6. Compared with dexamethasone, HP210 showed no cross activities with phylogenetically related mineralcorticoid receptor and progesterone receptor and no significant effect on osteoprotegerin, exhibiting a reduced side-effect profile. Then, guided by the molecular dynamics simulations and binding free energy calculations, compound HP210_b4 with over two-fold higher transrepression activity (IC50 = 0.99 μM) was discovered. This study reported a group of non-steroidal new-scaffold SGRMs, providing valuable clues for the development of novel anti-inflammatory drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI